News

2019.07.01News Release

Maruho Establishes New US Subsidiary,"Maruho America Inc."

2019.05.29News Release

Maruho and Welby Launch Smartphone App "Atopi Note" to Support Patients with Atopic Dermatitis

2019.04.18News Release

Nemolizumab Achieves Primary Endpoint in Phase 3 Clinical Study (Comparative Study) in Japan for the Treatment of Atopic Dermatitis

2019.03.29News Release

Maruho Announces a Transfer of Shares and a Change of a Consolidated Subsidiary

2019.03.04News Release

Maruho and Welby Launch Smartphone App "Nikibi Log" For Patients with Acne

2019.02.21News Release

Maruho and Asahi Kasei Pharma Announce First Approval in Japan of an Additional Dosage and Administration for Anti-herpes Virus Agent "Famvir^® Tab 250 mg" for the Treatment of Recurrent Herpes Simplex (Herpes labialis/Herpes genitalis)

2019.01.31News Release

Maruho and KOSÉ Agree to Establish a Jointly Owned Company

2019.01.30News Release

Chugai Transfers Rights to Maruho for Oxarol^® Ointment 25μg/g and Oxarol^® Lotion 25μg/g, Therapeutic Agents for Keratosis including Psoriasis Vulgaris, and Marduox^® Ointment, a Therapeutic Agent for Psoriasis Vulgaris

2018.10.01News Release

National Cancer Center Japan and Maruho Enter License Agreement and Research Collaboration Agreement for a Novel Analgesic for Stomatitis in Cancer Treatment

2018.09.28News Release

Maruho Succeeds Manufacturing and Marketing Approval and Marketing Rights for Acne Vulgaris Treatment Agent "Differin^® Gel 0.1%"

2018.09.13News Release

Maruho Launches Blood-flow Accelerative/Skin-moisturizing Agent "Hirudoid^® Foam 0.3%"

2018.07.05News Release

Nestlé Skin Health and Maruho Release Renewed Itch Measurement App 'Itch Tracker' for Apple Watch on July 5, Maruho Receives Exclusive Rights in Japan

2018.03.01News Release

Maruho Succeeds Manufacturing and Marketing Approval and Marketing Rights for Reduction of Malodor Generated in Cancerous Cutaneous Ulcers Treatment "Rozex^® Gel 0.75%"

2018.02.16News Release

Maruho Receives Manufacturing and Marketing Approval for Blood-flow Accelerative/Skin-moisturizing Agent "Hirudoid^® Foam 0.3%"

2018.01.22News Release

Maruho Launches In Vitro Diagnostic "DermaQuick^® VZV"

2017.12.25News Release

Maruho and RaQualia Enter License Agreement for Selective Sodium Channel Blocker